Pancreatic Cancer Stage III

What Stage III Means

T4 any N, M0 — Tumor involves celiac axis, superior mesenteric artery, or superior mesenteric vein; no distant metastases. Locally advanced unresectable.

Treatment Approach for Stage III

Neoadjuvant FOLFIRINOX for 4-6 months with reassessment for resectability. If resectable after downstaging, surgical resection. If unresectable after chemotherapy, continue palliative chemotherapy. Consider SBRT if chemotherapy plateau and good PS.

Survival Rates and Prognosis

The 5-year survival rate for pancreatic cancer at Stage III is approximately 5-year survival: 2-5% (median OS ~12-15 months with chemotherapy). Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.

Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.

How Other Stages Compare

Stage	5-Year Survival	Treatment
Stage IA	5-year survival: 14-20% in surgical series	Surgical resection (Whipple or distal pancreatectomy) followed by adjuvant…
Stage IB	5-year survival: 12-16% in surgical series	Surgical resection (Whipple or distal pancreatectomy) followed by adjuvant…
Stage IIA	5-year survival: 7-12% in surgical series	Neoadjuvant FOLFIRINOX preferred, then surgical resection if response adequate….
Stage IIB	5-year survival: 5-9% in surgical series	Neoadjuvant FOLFIRINOX for 2 months, restaging, then surgical resection if…
Stage IV	5-year survival: <5% (median OS ~6-9 months with FOLFIRINOX, ~8-10 months with gemcitabine/nab-paclitaxel)	Palliative systemic chemotherapy: FOLFIRINOX for fit patients (ECOG PS 0-1),…